MONTREAL, QUEBEC--(Marketwire - November 18, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced that the first patient has been enrolled in its Phase II trial evaluating TLN-232 as a treatment for metastatic melanoma in patients who have failed one prior therapy.
